Israel-based Medasense Biometrics has received approval to market its NOL pain response monitoring device (PMD-200) in Brazil.

The device is used by surgical teams to manage pain medication during surgery when the patient is under anaesthesia and unable to communicate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medasense’s NOL technology uses a non-invasive sensing platform and an artificial intelligence (AI) algorithm to objectively monitor and quantify the individual patient’s pain response.

It helps clinicians to optimise and personalise pain control and eliminate the chance of overmedication.

NOL technology is currently being assessed in the intensive care unit for mechanically ventilated patients, including Covid-19 patients, the company noted.

The outbreak of the Covid-19 pandemic in Brazil has resulted in a spike in the number of mechanically ventilated patients, requiring skilled pain management and optimal analgesia to help improve recovery.

Medasense has partnered with Brazilian company JG Moriya for the commercial launch of NOL pain response monitoring device in Brazil.

JG Moriya CEO Karine Moriya said: “Our network of influential surgeons and anesthesiologists should allow us to bring this much-needed technology to Brazil’s advanced surgical facilities and we expect to perform the first NOL-guided surgeries in the coming weeks.”

In September, Medasense Biometrics raised $18m in a Series C round from Sabadell Asabys venture capital company, Israeli family offices, and returning investors Baxter Ventures, Olive Tree Ventures, and LGL Capital.

The company will use the funds to expand and further consolidate commercial deployment of NOL technology in Europe through the distribution agreement with Medtronic.

Medasense is also pursuing the Food and Drug Administration (FDA) approval of the NOL pain response monitoring device in the US.